SCHEMBL5364730

SCHEMBL5364730

Cc1cccc(CNC2CCc3ccccc32)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.54
MAOA P21397 4/20 0.54
ACHE P22303 2/20 0.54
BCHE P06276 2/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
ADRA1A P35348 1/20 0.54
HTR6 P50406 1/20 0.54
PDPK1 O15530 1/20 0.50
KDM4E B2RXH2 3/20 0.49
BACE1 P56817 1/20 0.49
PRMT5 O14744 1/20 0.48
LMNA P02545 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
GRIN2B Q13224 1/20 0.44
FADS1 O60427 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146949 0.84 GRIN2B (0.62) MAOBMAOAACHEBCHEADRA2B
SCHEMBL2160788 0.84 GRIN2B (0.62) MAOBMAOAACHEBCHEADRA2B
SCHEMBL7149968 0.84 GRIN2B (0.62) MAOBMAOAACHEBCHEADRA2B
SCHEMBL18722296 0.84 GRIN2B (0.62) MAOBMAOAACHEBCHEADRA2B
Hydrochloric Acid SCHEMBL5969839 0.82 GRIN2B (0.60) MAOBMAOAACHEBCHEADRA2B
SCHEMBL6253383 0.81 KDM4E (0.58) KDM4EPRMT5LMNAKMT2A
SCHEMBL18768923 0.78 MAOB (0.50) MAOBMAOAACHEBCHEADRA2B
SCHEMBL7243872 0.77 GRIN2B (0.45) MAOBACHEBCHEBACE1LMNA
SCHEMBL6256318 0.76 KMT2A (0.53) KDM4EPRMT5LMNAKMT2A
SCHEMBL7050273 0.76 KDM4E (0.58) MAOAKDM4EPRMT5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3523292-B1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS DONG A SOCIO HOLDINGS CO LTD (KR) 2021-12-15 EP disclosed
US-7291621-B2 Substituted biaryl amides C5a receptor modulators NEUROGEN CORPORATION (US) 2007-11-06 US disclosed
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators C5AR1, C5AR2, C3AR1 MAOB 384/4885MAOA 357/4885ACHE 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.